# To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers

> **NCT03441984** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 36 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Treatment A
- **DRUG:** Treatment B
- **DRUG:** Treatment C
- **DRUG:** Treatment D
- **DRUG:** Treatment E
- **DRUG:** Treatment F

## Key facts

- **NCT ID:** NCT03441984
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-26
- **Primary completion:** 2018-04-28
- **Final completion:** 2018-04-28
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2019-12-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03441984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03441984, "To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03441984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*